Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Carcinoma, Non-Small-Cell Lung × PE regimen × Clear all

Phase

Status

Unknown 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 1 Progression Free Survival 1 Hormone Refractory Prostate Cancer 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Neuroendocrine 1

Interventions

Carboplatin 78 Cisplatin 77 Pemetrexed 64 Docetaxel 56 Erlotinib Hydrochloride 42 Gemcitabine 39 Paclitaxel 35 Gefitinib 33 Drug Therapy 32 Radiotherapy 31 osimertinib 26 icotinib 26 Bevacizumab 26 pembrolizumab 23 Vinorelbine 22 Nivolumab 22 anlotinib 21 camrelizumab 20 atezolizumab 15 Radiosurgery 15 Endostatins 15 aumolertinib 14 apatinib 14 endostar protein 13 durvalumab 13 sintilimab 12 Immune Checkpoint Inhibitors 9 Blood Specimen Collection 9 Surgical Procedures, Operative 8 Immunotherapy 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04828395 2021-05-11

F&C

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡